Most Clicked StoriesMore >


Bill would speed up FDA's review of EU-approved drugs

DIA Global SmartBrief | Mar 24, 2015

A bill was introduced by Reps. Steve Stivers, R-Ohio, and Tim Ryan, D-Ohio, to accelerate the FDA's review and approval of drugs that have been approved by the European Union. The Speeding Access to Already Approved Pharmaceuticals Act was proposed to address drug lag and delays in the availability of lifesaving and life-changing treatments in the U.S. The bill would require the FDA to review treatments that have been approved by European authorities within 90 days. The agency's current shortest assessment time is six months. Regulatory Focus (03/20)


DIA 2015 51st Annual Meeting

DIA Global SmartBrief | Mar 24, 2015

Eli Lilly, Innovent Biologics sign 10-year cancer drug deal

DIA Global SmartBrief | Mar 24, 2015

DIA's 27th Annual EuroMeeting

DIA Global SmartBrief | Mar 26, 2015

U.K. groups to fund multidisciplinary cancer research

DIA Global SmartBrief | Mar 26, 2015

Analysis shows $1B sales potential for Bristol-Myers, Sanofi, Novartis drugs

DIA Global SmartBrief | Mar 26, 2015

Phase I study finds Biogen's experimental drug stalls Alzheimer's

DIA Global SmartBrief | Mar 24, 2015

Phase I/II trial starts for acute myeloid leukemia vaccine

DIA Global SmartBrief | Mar 26, 2015

Researchers say immune system may hold key to malaria vaccine

DIA Global SmartBrief | Mar 24, 2015

Sanofi enters research-and-development alliance with Evotec

DIA Global SmartBrief | Mar 24, 2015


Find DIA Global SmartBrief Issues by Date:



DIA News More >


DIA's 27th Annual EuroMeeting

DIA Global SmartBrief | Mar 26, 2015

Urgent notice for DIA members

DIA Global SmartBrief | Mar 26, 2015

DIA 2015 51st Annual Meeting

DIA Global SmartBrief | Mar 24, 2015

Special notice for DIA members: The 2015 DIA Board of Directors election is underway!

DIA Global SmartBrief | Mar 19, 2015

DIA Clinical Forum 2015

DIA Global SmartBrief | Mar 19, 2015




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more